Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -12.04 is 90% above its 5-year average of -123.25, near the high end of its 5-year range (-334.60–-7.63).
49.57% below its 12-month average of -8.05.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -2.87.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 25 comparable quarters.
EARNINGS PER SHARE (EPS)
-12.04
EARNINGS PER SHARE (EPS) AVG TTM
-8.05
EARNINGS PER SHARE (EPS) AVG 3Y
-55.02
EARNINGS PER SHARE (EPS) AVG 5Y
-123.25
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
-49.57%
CURRENT VS 3Y AVG
+78.12%
CURRENT VS 5Y AVG
+90.23%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Korsana Biosciences, Inc.
Market Cap
$145.59M
Earnings Per Share (EPS)
-12.04
TTM Avg
-8.05
3Y Avg
-55.02
5Y Avg
-123.25
Market Cap
$143.76M
Earnings Per Share (EPS)
-1.04
TTM Avg
-1.66
3Y Avg
-1.77
5Y Avg
-1.60
Market Cap
$146.58M
Earnings Per Share (EPS)
-1.64
TTM Avg
-1.85
3Y Avg
-1.46
5Y Avg
-1.46
Market Cap
$146.71M
Earnings Per Share (EPS)
-0.61
TTM Avg
-0.35
3Y Avg
-0.32
5Y Avg
-0.30
Market Cap
$147.97M
Earnings Per Share (EPS)
-0.51
TTM Avg
-0.38
3Y Avg
-0.76
5Y Avg
-1.59
Market Cap
$140.10M
Earnings Per Share (EPS)
-2.52
TTM Avg
-2.32
3Y Avg
-1.91
5Y Avg
-1.63
Market Cap
$139.33M
Earnings Per Share (EPS)
-0.18
TTM Avg
-0.17
3Y Avg
-0.17
5Y Avg
-0.09
Market Cap
$138.69M
Earnings Per Share (EPS)
-1.11
TTM Avg
-1.59
3Y Avg
-2.87
5Y Avg
-3.93
Market Cap
$150.66M
Earnings Per Share (EPS)
-0.34
TTM Avg
-0.70
3Y Avg
-0.76
5Y Avg
-0.63
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Korsana Biosciences, Inc. (KRSA) | $145.59M | -12.04 | -8.05 | -55.02 | -123.25 |
| Immuneering Corporation (IMRX)vs › | $143.76M | -1.04 | -1.66 | -1.77 | -1.60 |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $146.58M | -1.64 | -1.85 | -1.46 | -1.46 |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $146.71M | -0.61 | -0.35 | -0.32 | -0.30 |
| LifeMD, Inc. (LFMDP)vs › | $147.97M | -0.51 | -0.38 | -0.76 | -1.59 |
| Nyxoah S.A. (NYXH)vs › | $140.10M | -2.52 | -2.32 | -1.91 | -1.63 |
| AirSculpt Technologies, Inc. (AIRS)vs › | $139.33M | -0.18 | -0.17 | -0.17 | -0.09 |
| Alpha Cognition Inc (ACOG)vs › | $138.69M | -1.11 | -1.59 | -2.87 | -3.93 |
| Codexis, Inc. (CDXS)vs › | $150.66M | -0.34 | -0.70 | -0.76 | -0.63 |
| Anavex Life Sciences Corp. (AVXL)vs › | $151.05M | -0.26 | -0.53 | -0.57 | -0.55 |
Trailing EPS (TTM)
$-12.04
Forward EPS (Est.)
$-3.27
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -7.63 |
| 2024-12-31 | -8.47 |
| 2023-12-31 | -62.93 |
| 2022-12-31 | -141.05 |
| 2021-12-31 | -184.80 |
| 2020-12-31 | -334.60 |
| 2019-12-31 | -618.59 |
| 2018-12-31 | -590.94 |
| 2017-12-31 | -481.60 |
| 2016-12-31 | -324.73 |
